Abstract 57P
Background
Expanded use of tumour molecular testing to enable targeted treatment across multiple cancers has increased identification of potential pathogenic germline variants (pPGVs). In NSCLC, BRCA1 and BRCA2 are two potentially targetable pPGVs that are not well described despite BRCA-mutated lung cancer accounting for 1%-14% of cases. This study evaluates the frequency of BRCA1/2-mutated NSCLC identified via tumour sequencing and describes patient and tumour characteristics, family history, clinical course, and germline BRCA mutational status.
Methods
NSCLC patients who underwent tumour testing between January 1, 2018 and June 30, 2021 were identified. Next generation sequencing was used to screen for 46 tumour gene mutations including BRCA1/2, with subsequent referral for germline testing via gene specific intronic polymerase chain reaction amplification if pPGVs were identified.
Results
Of 2784 patients with NSCLC who had tumour sequencing, 44 (1.6%) had pPGVs in BRCA1/2. The majority of patients had metastatic disease at diagnosis (59.1%) and a family history of cancer in a first-degree relative (56.8%), while 34.1% had personal history of a second primary cancer. Frequently co-mutated genes were TP53 (68.2%), KRAS (40.1%), and EGFR (20.5%). Of patients who had confirmatory testing, 60% (12/20) were confirmed germline BRCA1/2 carriers. Patients with stage IV disease at time of diagnosis with germline BRCA1/2 mutation had shortened overall survival (18.7 ± 4.6 months) when compared to the 8 patients with confirmed somatic BRCA1/2 mutation (63.8 ± 21.8 months, p = 0.027).
Conclusions
BRCA1/2 tumour mutations were detected with frequency consistent with prior reports and exhibit high likelihood of associated germline mutation. The observed difference in survival of patients with advanced disease harbouring somatic versus germline mutation warrants further study and highlights the importance of confirmatory germline testing as targeted therapies emerge in order to adequately prognosticate and inform families of at-risk status.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract